Document Detail


Hemodynamic effects of a new inotropic compound, PST-2744, in dogs with chronic ischemic heart failure.
MedLine Citation:
PMID:  12883318     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Inotropic agents for acute decompensated heart failure are associated with a lack of efficacy or increased mortality. New compounds are needed to support patients with acute exacerbations of heart failure. This study examined the hemodynamic effects of a new inotropic agent (PST-2744) in dogs with chronic ischemic heart failure. Eight mongrel dogs at low risk for postmyocardial infarction (MI) sudden death entered the protocol. Dogs were studied after ischemic left ventricular dysfunction was induced by repeated injections of latex microspheres into the circumflex artery until the ejection fraction reached 35%. Hemodynamic parameters were measured at baseline and peak drug effect (PST-2744 5 microg.kg-1.min-1). In 5 animals, PST-2744 effects were compared with dobutamine. Heart rates, PR intervals and QT intervals were unchanged following PST-2744 administration. PST-2744 increased contractility (+dP/dt) by 56% from 1881 +/- 282 mm Hg/s to 2939 +/- 734 mm Hg/s (P < 0.01). The inotropic effect of PST-2744 was equal to that produced by 5-microg.kg-1.min-1 dobutamine (56% increase in +dP/dt), but peak heart rates were significantly higher with dobutamine (129 +/- 24 bpm PST-2744 versus 160 +/- 6 bpm 5-microg.kg-1.min-1 dobutamine, P < 0.002). No arrhythmias or conduction delays were seen with either compound. PST-2744 is an effective inotropic agent without positive chronotropic effect in subjects with stable moderate left ventricular dysfunction.
Authors:
Philip B Adamson; Emilio Vanoli; Giovan G Mattera; Robin Germany; Jean-Pierre Gagnol; Paolo Carminati; Peter J Schwartz
Related Documents :
19346938 - The role of echocardiography in hemodynamic monitoring.
8362778 - Predictive value of dobutamine echocardiography just before noncardiac vascular surgery.
15757608 - Efficacy and safety of intermittent, long-term, concomitant dobutamine and levosimendan...
12461248 - Long-term prognostic value of dobutamine stress 99mtc-sestamibi spect: single-center ex...
1262778 - Spontaneous atrial premature depolarizations during paroxysmal reentrant tachycardia.
19387788 - Computational analysis of the effect of the type of lvad flow on coronary perfusion and...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Journal of cardiovascular pharmacology     Volume:  42     ISSN:  0160-2446     ISO Abbreviation:  J. Cardiovasc. Pharmacol.     Publication Date:  2003 Aug 
Date Detail:
Created Date:  2003-07-28     Completed Date:  2004-01-13     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  7902492     Medline TA:  J Cardiovasc Pharmacol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  169-73     Citation Subset:  IM    
Affiliation:
Department of Physiology, University of Oklahoma Health Sciences Center, 920 S.L. Young Boulevard, WP 3120, Oklahoma City, OK 73104, USA. Philip-adamson@ouhsc.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Cardiotonic Agents / pharmacology,  therapeutic use*
Dobutamine / pharmacology,  therapeutic use*
Dogs
Etiocholanolone / analogs & derivatives*,  pharmacology,  therapeutic use*
Heart Failure / drug therapy*
Hemodynamics / drug effects*
Ventricular Dysfunction, Left / drug therapy*
Grant Support
ID/Acronym/Agency:
R01 HL 66394/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/3-((2-aminoethoxy)imino)androstane-6,17-dione; 0/Cardiotonic Agents; 34368-04-2/Dobutamine; 53-42-9/Etiocholanolone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Verapamil, a Ca2+ entry blocker, targets the pore-forming subunit of cardiac type KATP channel (Kir6...
Next Document:  Inhibition of matrix metalloproteinases prevents cardiac hypertrophy induced by beta-adrenergic stim...